We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Buy Surging Lululemon Stock at New Highs Despite Coronavirus Setbacks?
Read MoreHide Full Article
Lululemon (LULU - Free Report) is set to report its first quarter fiscal 2020 financial results after the closing bell on Thursday, June 11. Shares of LULU have skyrocketed over the last few months despite the fact that many of its stores were closed due to the coronavirus.
Lululemon & the Pandemic
Lululemon in mid-March closed a “majority of” its stores “globally outside of Greater China” as part of the closure of countless businesses deemed non-essential. Lulu, like many other retail businesses from Apple (AAPL - Free Report) to restaurants, continued to run its e-commerce business.
LULU then announced on May 21 that it was in the process of “gradually welcoming guests back to select locations where it is permitted to do so.” The athleisure retailer had already reopened in Greater China and is currently working to reopen “market-by-market in accordance with local government and public health authority guidelines.”
Lululemon said at the time that it had already reopened “over 150 store locations across North America, Europe, Asia, New Zealand and Australia,” which is where a majority of its nearly 500 (as of the end Q4) stores are located. The company said at the time that it was planning on opening roughly 200 additional locations “over the next two weeks.”
Performance
Despite the closings and the uncertainty, LULU stock is up 130% since March 16 to crush stay-at-home stars such as Zoom (ZM - Free Report) , Amazon (AMZN - Free Report) , and Netflix (NFLX - Free Report) . Lululemon is now up 40% in 2020 and roughly 90% in the past 12 months.
Investors can also see that LULU has easily surpassed Nike (NKE - Free Report) and Adidas (ADDYY - Free Report) in the past two years, as part of much larger and longer run. And LULU hit new highs on Wednesday, up over 2% through late afternoon trading.
Outlook
Our current Zacks estimates call for LULU’s sales for the three-month period ended in early May to sink -9.6% from the year-ago period to $707.5 million. This would mark its first year-over-year revenue decline since Q4 of 2009 and represent a sharp drop from recent periods of 20% sales expansion.
LULU’s adjusted first quarter earnings are also projected to plummet 62% to $0.28 per share. However, Lulu’s full-year fiscal 2020 revenue is still projected to pop 3.2%, with FY21 expected to surge over 23% above our current year estimate. Meanwhile, its adjusted FY20 EPS figure is projected to slip 9%, with FY21 expected to surge 37% higher.
Bottom Line
Given its Q1 outlook, Wall Street has clearly proven it’s willing to look beyond Lululemon’s projected near-term setbacks as investors continue to bet on LULU’s longer-term growth within a booming industry that has seen everyone from Gap (GPS - Free Report) to Target (TGT - Free Report) try to emulate its offerings.
Lululemon’s mixed earnings revision activity helps it hold a Zacks Rank #3 (Hold) heading into its earnings release. LULU stock might face a post-earnings pullback no matter what its numbers say as investors take home some profits. That said, longer-term investors who were previously afraid to buy near its highs might have missed out on LULU’s massive run over the last three years, up over 500%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Buy Surging Lululemon Stock at New Highs Despite Coronavirus Setbacks?
Lululemon (LULU - Free Report) is set to report its first quarter fiscal 2020 financial results after the closing bell on Thursday, June 11. Shares of LULU have skyrocketed over the last few months despite the fact that many of its stores were closed due to the coronavirus.
Lululemon & the Pandemic
Lululemon in mid-March closed a “majority of” its stores “globally outside of Greater China” as part of the closure of countless businesses deemed non-essential. Lulu, like many other retail businesses from Apple (AAPL - Free Report) to restaurants, continued to run its e-commerce business.
LULU then announced on May 21 that it was in the process of “gradually welcoming guests back to select locations where it is permitted to do so.” The athleisure retailer had already reopened in Greater China and is currently working to reopen “market-by-market in accordance with local government and public health authority guidelines.”
Lululemon said at the time that it had already reopened “over 150 store locations across North America, Europe, Asia, New Zealand and Australia,” which is where a majority of its nearly 500 (as of the end Q4) stores are located. The company said at the time that it was planning on opening roughly 200 additional locations “over the next two weeks.”
Performance
Despite the closings and the uncertainty, LULU stock is up 130% since March 16 to crush stay-at-home stars such as Zoom (ZM - Free Report) , Amazon (AMZN - Free Report) , and Netflix (NFLX - Free Report) . Lululemon is now up 40% in 2020 and roughly 90% in the past 12 months.
Investors can also see that LULU has easily surpassed Nike (NKE - Free Report) and Adidas (ADDYY - Free Report) in the past two years, as part of much larger and longer run. And LULU hit new highs on Wednesday, up over 2% through late afternoon trading.
Outlook
Our current Zacks estimates call for LULU’s sales for the three-month period ended in early May to sink -9.6% from the year-ago period to $707.5 million. This would mark its first year-over-year revenue decline since Q4 of 2009 and represent a sharp drop from recent periods of 20% sales expansion.
LULU’s adjusted first quarter earnings are also projected to plummet 62% to $0.28 per share. However, Lulu’s full-year fiscal 2020 revenue is still projected to pop 3.2%, with FY21 expected to surge over 23% above our current year estimate. Meanwhile, its adjusted FY20 EPS figure is projected to slip 9%, with FY21 expected to surge 37% higher.
Bottom Line
Given its Q1 outlook, Wall Street has clearly proven it’s willing to look beyond Lululemon’s projected near-term setbacks as investors continue to bet on LULU’s longer-term growth within a booming industry that has seen everyone from Gap (GPS - Free Report) to Target (TGT - Free Report) try to emulate its offerings.
Lululemon’s mixed earnings revision activity helps it hold a Zacks Rank #3 (Hold) heading into its earnings release. LULU stock might face a post-earnings pullback no matter what its numbers say as investors take home some profits. That said, longer-term investors who were previously afraid to buy near its highs might have missed out on LULU’s massive run over the last three years, up over 500%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>